226 related articles for article (PubMed ID: 28237836)
21. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
Diaz RM; Galivo F; Kottke T; Wongthida P; Qiao J; Thompson J; Valdes M; Barber G; Vile RG
Cancer Res; 2007 Mar; 67(6):2840-8. PubMed ID: 17363607
[TBL] [Abstract][Full Text] [Related]
22. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
23. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
26. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
28. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.
Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Pulido J; Pavelko K; Pease L; Melcher A; Vile R
Cancer Res; 2010 Jun; 70(11):4539-49. PubMed ID: 20484025
[TBL] [Abstract][Full Text] [Related]
29. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
30. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
31. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
32. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
33. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
34. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG
Mol Ther; 2008 Dec; 16(12):1910-8. PubMed ID: 18827807
[TBL] [Abstract][Full Text] [Related]
35. Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.
Gao Y; Whitaker-Dowling P; Griffin JA; Bergman I
Cancer Gene Ther; 2012 Apr; 19(4):282-91. PubMed ID: 22240921
[TBL] [Abstract][Full Text] [Related]
36. Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers.
Melzer MK; Zeitlinger L; Mall S; Steiger K; Schmid RM; Ebert O; Krackhardt A; Altomonte J
Mol Ther Oncolytics; 2019 Mar; 12():26-40. PubMed ID: 30662938
[TBL] [Abstract][Full Text] [Related]
37. Antigen processing of vesicular stomatitis virus in situ. Interdigitating dendritic cells present viral antigens independent of marginal dendritic cells but fail to prime CD4(+) and CD8(+) T cells.
Ciavarra RP; Greene AR; Horeth DR; Buhrer K; van Rooijen N; Tedeschi B
Immunology; 2000 Dec; 101(4):512-20. PubMed ID: 11122455
[TBL] [Abstract][Full Text] [Related]
38. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.
Publicover J; Ramsburg E; Rose JK
J Virol; 2005 Nov; 79(21):13231-8. PubMed ID: 16227246
[TBL] [Abstract][Full Text] [Related]
39. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
